A new design method reported in the ADC space claims to increase potency against heterogeneous tumors by improving how antibody-drug conjugates engage multi-receptor biology. The approach targets a common limitation in many ADC programs: antibodies are often optimized for a single receptor type, leaving heterogeneous tumors partially unaddressed. Separately, multiple analytical and regulatory perspectives continue to emphasize that ADCs require tightly integrated measurement and risk management across antibody, linker, and payload—because manufacturing variability can translate into meaningful changes in exposure and safety. Taken together, the developments reinforce that “potency” in ADCs is not only a chemistry question; it depends on how the drug is engineered, manufactured, and characterized at scale under evolving regulatory expectations.